[ad_1]
Leerink raised the agency’s value goal on Vertex Prescription drugs (VRTX) to $525 from $456 and retains an Outperform score on the shares. The agency cites a rise in its terminal progress assumption from 1% to 2%. Leerink is optimistic in regards to the firm’s income and pipeline prospects, which it expects to drive inventory value efficiency. The agency would caveat that it tasks larger funding spending progress than consensus fashions.
Revealed first on TheFly – the last word supply for real-time, market-moving breaking monetary information. Attempt Now>>
See the highest shares really helpful by analysts >>
Learn Extra on VRTX:
[ad_2]
